Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938559664> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2938559664 endingPage "1546" @default.
- W2938559664 startingPage "1540" @default.
- W2938559664 abstract "Background Vision loss and other ocular toxicities are rare, but detrimental, side effects of immune checkpoint inhibitors. Herein, we report two patients who developed vision loss while on pembrolizumab treatment. Cases presentation Case 1 – A 58-year-old man was started on pembrolizumab for advanced melanoma. He was tolerating the treatment well. After receiving 14 cycles of pembrolizumab, he developed acute bilateral vision loss and occipital headaches. An emergent ophthalmologic evaluation revealed bilateral shallow choroidal effusion with bilateral focal exudative retinal detachment. After excluding other possible etiologies, inflammatory process secondary to pembrolizumab was suspected. Pembrolizumab was stopped, and the patient was started on a course of systemic and topical steroids. His vision improved within days and he recovered completely within two months. Calculated Naranjo Nomogram score was 7 indicating a “probable” correlation; Case 2 – A 57-year-old man with stage IIIC melanoma was started on adjuvant pembrolizumab. After a few weeks of treatments, he reported minor bilateral vision changes that progressively worsened over a period of six months. An ophthalmologic evaluation revealed bilateral posterior uveitis with right optic disc edema. Pembrolizumab-related inflammatory changes were suspected, and he was started on systemic and topical steroids. His symptoms improved within a few weeks and steroids were tapered. He was re-challenged with pembrolizumab and his symptoms quickly re-occurred. Pembrolizumab was stopped indefinitely and the patient again treated with systemic and topical steroids. His symptoms resolved and his vision returned to baseline within two months. The Naranjo Nomogram score was 9 indicating a “definite” correlation. Conclusions Vision loss is a serious complication that may occur at any point during treatment with PD-1 inhibitors. Vision loss is very distressing to the patients and their families. It is prudent for practitioners to recognize early vision abnormalities in patients receiving PD-1 antagonists to prevent permanent vision loss." @default.
- W2938559664 created "2019-04-25" @default.
- W2938559664 creator A5002327469 @default.
- W2938559664 creator A5044001272 @default.
- W2938559664 creator A5085936753 @default.
- W2938559664 date "2019-04-18" @default.
- W2938559664 modified "2023-09-23" @default.
- W2938559664 title "Vision loss with pembrolizumab treatment: A report of two cases" @default.
- W2938559664 cites W2008828780 @default.
- W2938559664 cites W2061952603 @default.
- W2938559664 cites W2067978628 @default.
- W2938559664 cites W2201460159 @default.
- W2938559664 cites W2250524839 @default.
- W2938559664 cites W2266680384 @default.
- W2938559664 cites W2344489622 @default.
- W2938559664 cites W2486996368 @default.
- W2938559664 cites W2510997244 @default.
- W2938559664 cites W2517761860 @default.
- W2938559664 cites W2521389196 @default.
- W2938559664 cites W2521587286 @default.
- W2938559664 cites W2526699566 @default.
- W2938559664 cites W2530468309 @default.
- W2938559664 cites W2536144887 @default.
- W2938559664 cites W2768429453 @default.
- W2938559664 cites W2770097316 @default.
- W2938559664 cites W2772873340 @default.
- W2938559664 cites W2791219690 @default.
- W2938559664 cites W2795500173 @default.
- W2938559664 cites W2811286837 @default.
- W2938559664 cites W2884236494 @default.
- W2938559664 cites W2895887225 @default.
- W2938559664 cites W2900355533 @default.
- W2938559664 doi "https://doi.org/10.1177/1078155219841683" @default.
- W2938559664 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30997872" @default.
- W2938559664 hasPublicationYear "2019" @default.
- W2938559664 type Work @default.
- W2938559664 sameAs 2938559664 @default.
- W2938559664 citedByCount "18" @default.
- W2938559664 countsByYear W29385596642019 @default.
- W2938559664 countsByYear W29385596642020 @default.
- W2938559664 countsByYear W29385596642021 @default.
- W2938559664 countsByYear W29385596642022 @default.
- W2938559664 countsByYear W29385596642023 @default.
- W2938559664 crossrefType "journal-article" @default.
- W2938559664 hasAuthorship W2938559664A5002327469 @default.
- W2938559664 hasAuthorship W2938559664A5044001272 @default.
- W2938559664 hasAuthorship W2938559664A5085936753 @default.
- W2938559664 hasConcept C118487528 @default.
- W2938559664 hasConcept C121608353 @default.
- W2938559664 hasConcept C126322002 @default.
- W2938559664 hasConcept C141071460 @default.
- W2938559664 hasConcept C16005928 @default.
- W2938559664 hasConcept C2776194053 @default.
- W2938559664 hasConcept C2777701055 @default.
- W2938559664 hasConcept C2780057760 @default.
- W2938559664 hasConcept C2780966972 @default.
- W2938559664 hasConcept C71924100 @default.
- W2938559664 hasConceptScore W2938559664C118487528 @default.
- W2938559664 hasConceptScore W2938559664C121608353 @default.
- W2938559664 hasConceptScore W2938559664C126322002 @default.
- W2938559664 hasConceptScore W2938559664C141071460 @default.
- W2938559664 hasConceptScore W2938559664C16005928 @default.
- W2938559664 hasConceptScore W2938559664C2776194053 @default.
- W2938559664 hasConceptScore W2938559664C2777701055 @default.
- W2938559664 hasConceptScore W2938559664C2780057760 @default.
- W2938559664 hasConceptScore W2938559664C2780966972 @default.
- W2938559664 hasConceptScore W2938559664C71924100 @default.
- W2938559664 hasIssue "6" @default.
- W2938559664 hasLocation W29385596641 @default.
- W2938559664 hasLocation W29385596642 @default.
- W2938559664 hasOpenAccess W2938559664 @default.
- W2938559664 hasPrimaryLocation W29385596641 @default.
- W2938559664 hasRelatedWork W2003938723 @default.
- W2938559664 hasRelatedWork W2010519611 @default.
- W2938559664 hasRelatedWork W2047967234 @default.
- W2938559664 hasRelatedWork W2118496982 @default.
- W2938559664 hasRelatedWork W2201460159 @default.
- W2938559664 hasRelatedWork W2364998975 @default.
- W2938559664 hasRelatedWork W2439875401 @default.
- W2938559664 hasRelatedWork W2554635175 @default.
- W2938559664 hasRelatedWork W4238867864 @default.
- W2938559664 hasRelatedWork W2525756941 @default.
- W2938559664 hasVolume "25" @default.
- W2938559664 isParatext "false" @default.
- W2938559664 isRetracted "false" @default.
- W2938559664 magId "2938559664" @default.
- W2938559664 workType "article" @default.